RPE65 and Leber congenital amaurosis 2: The major breakthrough in retinal gene therapy was realized in 2017 for FDA approval of AAV vector Luxturna‐mediated gene therapy for Leber congenital amaurosis type 2 (LCA2), which is caused by RPE65 mutations leading to severely impaired vision at birth and then slowly progressive degeneration of retinal photoreceptors [190].